Literature DB >> 16321530

Synthesis and anti-HSV-1 activity of quinolonic acyclovir analogues.

Bianca d'A Lucero1, Claudia Regina B Gomes, Izabel Christina de P P Frugulhetti, Letícia V Faro, Lise Alvarenga, Maria Cecília B V de Souza, Thiago M L de Souza, Vitor F Ferreira.   

Abstract

Several 1-[(2-hydroxy-ethoxy)methyl]-3-carbethoxy-4(1H)quinolones (2a-l) and l-[(2-hydroxy-ethoxy)methyl]-4(1H)quinolone-3-carboxylic acids (3a-j and 3l) were synthesized and 2a-j, 2l and 3a-j, 3l were evaluated against herpes simplex virus type 1 (HSV-1), employing a one-pot reaction: silylation of the desired quinolone (BSTFA 1% TMCS) followed by equimolar amount addition of 1,3-dioxolane, chlorotrimethylsilane and KI, at room temperature. The acyclonucleosides 2a-l were obtained in 40-77% yields. The esters 2a-j and 2l were subsequently converted into the corresponding hydroxyacids 3 in 40-70% yields. Attempts of hydrolysis of 2k produced only a mixture of degradation products. Antiviral activity of 2 and 3 on HSV-1 virus infection was assessed by the virus yield assay. Except for compounds 2i and 3e, the acyclonucleosides were found to reduce the virus yield by 70-99% at the concentration of 50 microM, being the acids, in general, more effective inhibitors than their corresponding esters. Compounds 3j and 2d exhibited antiviral activity against HSV-1 virus with EC50 of 0.7+/-0.04 and 0.8+/-0.09 microM, respectively. Both compounds were not toxic towards the Vero cell line.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16321530     DOI: 10.1016/j.bmcl.2005.10.111

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

1.  Synthesis and structure-activity relationships of antimalarial 4-oxo-3-carboxyl quinolones.

Authors:  Yiqun Zhang; W Armand Guiguemde; Martina Sigal; Fangyi Zhu; Michele C Connelly; Solomon Nwaka; R Kiplin Guy
Journal:  Bioorg Med Chem       Date:  2010-02-11       Impact factor: 3.641

2.  Oxoquinoline derivatives: identification and structure-activity relationship (SAR) analysis of new anti-HSV-1 agents.

Authors:  Paula A Abreu; Viveca A G G da Silva; Fernanda C Santos; Helena C Castro; Cecília S Riscado; Mariana T de Souza; Camilly P Ribeiro; Juliana E Barbosa; Cláudio C C dos Santos; Carlos R Rodrigues; Viviane Lione; Bianca A M Correa; Anna C Cunha; Vitor F Ferreira; Maria C B V de Souza; Izabel C N P Paixão
Journal:  Curr Microbiol       Date:  2011-01-12       Impact factor: 2.188

3.  (E)-1-Ethyl-4-oxo-N'-(4-pyridylmethyl-ene)-1,4-dihydroquinoline-3-carbo-hydrazide.

Authors:  Fernanda da C Santos; Pedro Netto Batalha; Anna Claudia Cunha; Rafael A Alão; Vitor Francisco Ferreira; Maria Cecilia B V de Souza; Sauli Santos
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-09-16

4.  Design, synthesis, molecular docking, and antibacterial evaluation of some novel flouroquinolone derivatives as potent antibacterial agent.

Authors:  Mehul M Patel; Laxman J Patel
Journal:  ScientificWorldJournal       Date:  2014-12-09

5.  Cyclopropanation-ring expansion of 3-chloroindoles with α-halodiazoacetates: novel synthesis of 4-quinolone-3-carboxylic acid and norfloxacin.

Authors:  Sara Peeters; Linn Neerbye Berntsen; Pål Rongved; Tore Bonge-Hansen
Journal:  Beilstein J Org Chem       Date:  2019-09-13       Impact factor: 2.883

6.  Inhibitory properties of crude microalgal extracts on the in vitro replication of cyprinid herpesvirus 3.

Authors:  Stefanie Fritzsche; Patrik Blenk; Jürgen Christian; Kathrin Castiglione; Anna Maria Becker
Journal:  Sci Rep       Date:  2021-11-30       Impact factor: 4.379

Review 7.  Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.

Authors:  Temilolu Idowu; Frank Schweizer
Journal:  Antibiotics (Basel)       Date:  2017-11-07

8.  In vitro inhibition and molecular docking of a new ciprofloxacin-chalcone against SARS-CoV-2 main protease.

Authors:  Rania Alaaeldin; Muhamad Mustafa; Gamal El-Din A Abuo-Rahma; Moustafa Fathy
Journal:  Fundam Clin Pharmacol       Date:  2021-07-30       Impact factor: 2.747

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.